西达苯胺联合抗骨髓瘤药物对骨髓瘤细胞的增殖及凋亡的影响

The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells

目的:探讨西达苯胺联合抗骨髓瘤药物对骨髓瘤细胞的增殖及凋亡的影响。方法:用CCK-8法检测细胞的增殖抑制,流式细胞术检测细胞的凋亡变化。结果:西达苯胺以时间、剂量依赖性方式抑制骨髓瘤细胞的增殖(NCI-H929,r=0.720;MM.1s,r=0.636),同时促进原代骨髓瘤浆细胞的凋亡。在NCI-H929细胞系上,西达苯胺联合低剂量硼替佐米、来那度胺具有协同作用,联合地塞米松、泊马度胺具有相加作用;在MM.1s细胞系上,西达苯胺联合硼替佐米、地塞米松、来那度胺、泊马度胺均具有协同作用。结论:西达苯胺以时间、剂量依赖方式抑制骨髓瘤细胞的增殖,促进原代骨髓瘤浆细胞的凋亡,并增强抗骨髓瘤药物的抑制作用。

Objective: To investigate the effects of chidamide combined with anti-myeloma drugs on the proliferation and apoptosis of myeloma cells. Methods: The proliferation inhibition of the cells was detected by CCK-8 method, and flow cytometry was used to detected the apoptosis of the cells. Results: Chidamide could inhibit the proliferation of myeloma cells and promote the apoptosis of primary myeloma plasma cells in a time-and dose-dependent manner(P<0.05).In NCI-H929 cell line, chidamide combined with low-dose bortezomib and lenalidomide showed synergistic effect, while combined with dexamethasone and pomalidomide showed additive effect. In MM.1 s cell line, chidamide combined with bortezomib, dexamethasone, lenalidomide and pomalidomide all showed synergistic effects. Conclusion: Chidamide inhibits proliferation of myeloma cells in a time-and dose-dependent manner and promotes apoptosis of primary myeloma plasma cells. Furthermore, it can enhance the inhibitory effect of anti-myeloma drugs.